ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MRVI vs VERA // EV/EBITDA & P/E VALUATION

Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) VS. Vera Therapeutics Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: MRVI 3 — VERA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRVI VS. VERA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MRVI VERA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 18.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -3.22% -10.99% +7.77 MRVI /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -28.30% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.04 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 MRVI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.6 52.8 +0.76 MRVI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.20B $2.20B -$3.3M VERA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MRVI REV VERA REV MRVI GROSS % VERA GROSS % MRVI FCF VERA FCF
FY 2025 $185.7M $0 18.3% — -$70.7M -$241.7M
FY 2024 $259.2M $0 41.8% — -$22.2M -$135.7M
FY 2023 $288.9M $0 — — $126.2M -$92.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRVI // BETA —
VERA // BETA —